Develops gene therapies for inherited retinal diseases.
Jun 2026Revenue $9.86M/yrExpenses $60.5M/yr
No trendCash runway ≈ 2.2 years from Jun 2026
Figures by year
When will Opus Genetics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $9.86M and expenses $60.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $14.2M | $52.8M | −$38.6M |
| Dec 2024 | $11.0M | $73.1M | −$62.1M |
| Dec 2023 | $19.0M | $29.6M | −$10.6M |
| Dec 2022 | $39.9M | $21.6M | $18.2M |
| Dec 2021 | $589K | $23.3M | −$22.7M |
| Dec 2020 | $0.00 | $20.0M | −$20.0M |
| Dec 2019 | $3.00M | $7.19M | −$4.19M |
| Dec 2013 | $0.00 | $7.98M | −$7.98M |
| Dec 2012 | $0.00 | $6.58M | −$6.58M |
| Dec 2011 | $0.00 | $16.1M | −$16.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.